Evidence map›Paper›PMID 33868015›Full record

ArticleFrontiers in physiology2021

MiR-22 Inhibition Alleviates Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy by Targeting the sirt1/PGC-1α Pathway.

Runze Wang, Yuerong Xu, Xiaolin Niu, Yexian Fang, Dong Guo, Jiangwei Chen, Hanzhao Zhu, Jiaying Dong, Ran Zhao, Ying Wang and 5 more

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity.International journal of molecular sciences · 2022
    Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Runze WangDepartment of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Yuerong XuDepartment of Orthodontics, School of Stomatology, The Fourth Military Medical University, Xi'an, China.
Xiaolin NiuDepartment of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Yexian FangDepartment of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Dong GuoDepartment of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Jiangwei ChenDepartment of Cardiology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Hanzhao ZhuDepartment of Cardiovascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Jiaying DongDepartment of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Ran ZhaoDepartment of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Ying WangDepartment of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Bingchao QiDepartment of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Gaotong RenDepartment of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Xue LiDepartment of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Li LiuDepartment of Hematology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Mingming ZhangDepartment of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Air Force Medical University · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (DOX) cardiotoxicity is a life-threatening side effect that leads to a poor prognosis in patients receiving chemotherapy. We investigated the role of miR-22 in doxorubicin-induced cardiomyopathy and the underlying mechanism

Indexed as

doxorubicinmiR-22mitochondrial dysfunctionmitophagyoxidative stress

Identifiers

PMID33868015
PMCPMC8047466
OpenAlexW3150493014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.